Efficacy of autologous hematopoietic stem cell transplantation for 44 patients with lymphoma

Abstract:

Objective：To evaluate the clinical efficacy of autologous hematopoietic stem cell transplantation（AHSCT） in the treatment of lymphoma. Methods：Clinical data of 45 patients with lymphoma who received AHSCT in our hospital stem cell transplant cen－ter were retrospectively analyzed. All patients with lymphoma achieved complete remission or partial remission after several courses of radiotherapy and chemotherapy，and then they received AHSCT and follow-up treatment in our hospital. Results：Among 44 patients treated by AHSCT，1 patient died of cardiac toxicity induced by cyclophosphamide in the pretreatment and the other 43 patients all obtained hematopoietic reconstitution；the median follow-up time was 17（1-53） months. Thirty-two patients survived（74%） and 11 died among the 43 patients who had successful AHSCT. Nine patients（21%） died in the period of palliative care after recurrence，1 patient died of viral hepatitis B and 1 patient died of evans syndrome among the 11 died patients.Both the overall rate and disease-free survival rate was 72% until follow-up finished. Means survival time was （3.7±0.6） years，3-year survival rate was 68% and estimated 5-year survival rate was 51%. Conclusions：With the advantages of ripe technical conditions，wide range of in－dications and significant treatment effect，AHSCT is the important part of treatment regimens for lymphoma .